The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit organization developing new treatments for drug-resistant infections that pose the greatest threat to health. GARDP works with partners to ensure sustainable access to treatments, promoting responsible use and affordability to all in need.
Antibiotics radically transformed our world by making previously incurable illnesses treatable and allowing medical procedures like chemotherapy and operations to be performed safely. Millions of lives have been saved and our well-being and lifespans improved as a result. This remarkable progress is threatened by antibiotic resistance and requires an urgent global response.
GARDP mobilizes partners to develop new and improved antibiotics. In partnership with governments, the private sector, academia and civil society, we are embracing innovative solutions to antibiotic resistance.
Created by the World Health Organization (WHO) and Drugs for Neglected Diseases initiative (DNDi), GARDP is essential to delivering on the Global Action Plan on Antimicrobial Resistance.
The unchecked growth of drug-resistant infections – which are increasingly hard to treat – is a silent pandemic with long-term consequences for global public health and the global economy. According to recently released data published in the Lancet, at least 1.27 million people died of drug resistant infections in 2019. Antimicrobial resistance (AMR) also threatens the viability of surgical and curative medical interventions, such as chemotherapy. It is no longer a threat with future consequences, but a complex existential emergency of infections by multiple microbes. Many countries lack access to existing antibiotics, while in other countries rising rates of resistance require new treatments that have not yet been developed. Drug-resistant infections are a long-term challenge for which governments, including through G7 leadership, as well as the private sector, and civil society, must construct a durable infrastructure to prepare and respond. One pressing concern is for this infrastructure to ensure sustained research and development of novel antibiotics that address priority infections, and responsible access to novel and existing antibiotics to save lives and assure the long-term viability of such critical countermeasures.